Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Operating Expenses: 2019-2024

Historic Other Operating Expenses for Catalyst Pharmaceuticals (CPRX) over the last 6 years, with Dec 2024 value amounting to $106.2 million.

  • Catalyst Pharmaceuticals' Other Operating Expenses rose 11.80% to $32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.2 million, marking a year-over-year increase of 20.08%. This contributed to the annual value of $106.2 million for FY2024, which is 25.66% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Other Operating Expenses stood at $106.2 million for FY2024, which was up 25.66% from $84.5 million recorded in FY2023.
  • In the past 5 years, Catalyst Pharmaceuticals' Other Operating Expenses registered a high of $106.2 million during FY2024, and its lowest value of $17.0 million during FY2020.
  • Moreover, its 3-year median value for Other Operating Expenses was $84.5 million (2023), whereas its average is $75.4 million.
  • Data for Catalyst Pharmaceuticals' Other Operating Expenses shows a peak YoY skyrocketed of 138.18% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Catalyst Pharmaceuticals' Other Operating Expenses stood at $17.0 million in 2020, then increased by 28.43% to $21.9 million in 2021, then spiked by 62.18% to $35.5 million in 2022, then skyrocketed by 138.18% to $84.5 million in 2023, then grew by 25.66% to $106.2 million in 2024.